Provided below are an analysts forecasts of revenue, net operating profit after tax (NOPAT), and net operating assets (NOA) as of 12/31/2022 for Abbott Laboratories.

According to the DCF model, what is the total value of the firm? [ Select ] ["$28,562.0", "$32,387.5", "$261,990.4", "$18,284.2", "$233,920.0"] According to the DCF model, what is the value per share of common stock? [ Select ] ["$20.54", "$16.44", "$10.52", "$151.00", "$130.17"] The companys stock closed at $106.74 on 02/17/2023, the date the 10-K was filed with the SEC. In comparing your valuation estimate (also known as intrinsic value) with the actual stock price, was the stock overvalued or undervalued, and why? [ Select ] ["Undervalued, because the stock price is less than intrinsic value", "Overvalued, because intrinsic value is more than the stock price", "Overvalued, because the stock price is more than intrinsic value", "Undervalued, because intrinsic value is less than the stock price"]

This is multiple choice with possible answers above.

The following additional information is provided (dollar and share amounts in millions). - Common shares outstanding: 1,737.795 - Net nonoperating obligations (NNO): \$7,490.0 - Noncontrolling interest (NCl):$219.0 - Preferred stock: $0.0 - WaCC: 5.0% - Terminal growth: 2.0% Use the discounted cash flow (DCF) method to answer the following questions. Do not round intermediate calculations. All values other than per-share amounts are shown in millions. The following additional information is provided (dollar and share amounts in millions). - Common shares outstanding: 1,737.795 - Net nonoperating obligations (NNO): \$7,490.0 - Noncontrolling interest (NCl):$219.0 - Preferred stock: $0.0 - WaCC: 5.0% - Terminal growth: 2.0% Use the discounted cash flow (DCF) method to answer the following questions. Do not round intermediate calculations. All values other than per-share amounts are shown in millions